<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02742467</url>
  </required_header>
  <id_info>
    <org_study_id>Project8264</org_study_id>
    <nct_id>NCT02742467</nct_id>
  </id_info>
  <brief_title>Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans</brief_title>
  <acronym>Creole</acronym>
  <official_title>Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Abuja</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Edouard Herriot</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Nairobi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ibadan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital General De Douala</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mulago Hospital, Uganda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Abuja</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The creole study is a A Multi-centre, multinational, randomised single-blind, parallel group,
      three-armed superiority trial which is aimed at comparing the efficacy of three &quot;free&quot;
      combinations of two anti-hypertensive agents on 24 hour ambulatory systolic blood pressure
      (ASBP) in black African hypertensive patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CREOLE trial will be performed at ten investigational sites in six countries in
      Sub-Saharan Africa which include Cameroun, Kenya, Mozambique, Nigeria, South Africa and
      Uganda. Subjects will be randomised to one of three treatments which are Perindopril plus
      Amlodipine or Perindopril plus Hydrochlorothiazide or Amlodipine plus
      Hydrochlorothiazide.Patients will commence treatment at a starting dose of Amlodipine plus
      Hydrochlorothiazide 5/12.5 mg or Amlodipine plus Perindopril 5/4 mg or
      Perindopril/Hydrochlorothiazide 4/12.5 mg. These doses will increase at the two months visit,
      to Amlodipine/Hydrochlorothiazide 10/25 mg or AmlodipinePperindopril 10/8mg or
      Perindopril/Hydrochlorothiazide 8/25 mg.

      The patients will have ambulatory blood pressure monitoring at randomization and at six
      months and office blood pressure measurements at randomization and at two-month, 4-month and
      six-month visits.The overall aim is to discover the best combination of front-line
      anti-hypertensive medications for black patients residing in sub-Saharan Africa.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ambulatory blood pressure measurement from baseline to 6 months</measure>
    <time_frame>six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 24 hour ambulatory diastolic blood pressure</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinic systolic and diastolic BP</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in daytime and night time BP</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in BP variability measured by ASBP</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who achieve BP control (defined as clinic BP &lt; 140/90 mmHg)</measure>
    <time_frame>Two months and six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of &quot;responders&quot; (defined as clinic BP reduction &gt; 20mmHg SBP and &gt;10 mmHg DBP)</measure>
    <time_frame>Two months and six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in micro- and macro-albuminuria</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting blood sugar</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting lipid profile</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">702</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Perindopril plus Amlodipine at a dose of 4mg/5mg once daily for two months and 8mg/10mg once daily for the remaining four months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Perindopril Plus Hydrochlorothiazide at a dose of 4mg/12.5mg and 8mg/25mg once daily for the remaining four months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amlodipine plus Hydrochlorothiazide 5mg/12.5mg for two months and 10mg/25mg for the remaining four months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perindopril plus Amlodipine</intervention_name>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perindopril plus Hydrochlorothiazide</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine plus Hydrochlorothiazide</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Sitting SBP ≥140 mm Hg and &lt; 160 mmHg on one antihypertensive agen or

          -  Sitting SBP ≥ 150 mm Hg and &lt; 180 mm Hg on no antihypertensive treatment.

        Exclusion Criteria:

          -  Congestive heart failure (clinically defined).

          -  Serum creatinine levels greater than 170 µmol/l or estimated glomerular filtration
             rate (eGFR) &lt; 30 ml/min.

          -  History of coronary heart disease (i.e., chronic stable angina, myocardial infarction
             or acute coronary syndrome).

          -  History of a stroke or other cerebrovascular accident (i.e. transient ischaemic attack
             or reversible ischaemic neurological deficit).

          -  Known or suspected secondary hypertension.

          -  Any other concomitant illness, physical or mental impairment that could interfere with
             the effective conduct of the study.

          -  Pregnancy or those of child-bearing age who are not taking reliable contraception.

          -  Patients with a history of intolerance to any of the study medications for example
             angioedema or dry cough with angiotensin converting enzyme inhibitors.

          -  Patients on maximum dose of any of the study medications as monotherapy (i.e.
             amlodipine 10 mg/day or hydrochlorothiazide 25 mg/day or perindopril 8 mg/day)

          -  Gout.

          -  Serum potassium &lt; 3.5mmol/L at screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Poulter, MD, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bongani Mayosi, DPhil</last_name>
    <role>Study Chair</role>
    <affiliation>University of Cape Town</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dike Ojji, PhD</last_name>
    <phone>+2348060094456</phone>
    <email>dikeojji@yahoo.co.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lakai Shedul, MD</last_name>
    <phone>+2347085358633</phone>
    <email>shedulinks@yahoo.com</email>
  </overall_contact_backup>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2016</study_first_submitted>
  <study_first_submitted_qc>April 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2016</study_first_posted>
  <last_update_submitted>April 18, 2016</last_update_submitted>
  <last_update_submitted_qc>April 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Abuja</investigator_affiliation>
    <investigator_full_name>Dr. Dike Ojji</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Perindopril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

